• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
MYX
Click for more information
3.56% $4.60

MAYNE PHARMA GROUP LIMITED - News & Media

Market Cap $400.6M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare

Mayne Pharma Group Limited is an Australia-based specialty pharmaceutical company focused... Mayne Pharma Group Limited is an Australia-based specialty pharmaceutical company focused on commercializing novel pharmaceuticals. The Company also provides contract development and manufacturing services to clients worldwide. The Company’s segments include Women’s Health, Dermatology, and International. The Women’s Health segment distributes women’s health branded products in the United States. This segment includes NEXTSTELLIS, ANNOVERA, BIJUVA, IMVEXXY and branded pre-natal vitamins. The Dermatology segment distributes established dermatology products in the United States. The International segment is engaged in the manufacture and sale of branded and generic pharmaceutical products globally and the provision of contract development and manufacturing services to third party customers. The Company's products include ACTIKERALL Solution, ASTRIX Capsules and Tablets, MAGNOPLASM Paste and SPLINTEX Splinter Removal Gel, and ANNOVERA Vaginal Ring, among others.More

Articles & Videos

Mayne Pharma to pay A$33M in class action settlement on alleged US conduct

Mayne Pharma (ASX:MYX) has announced it will pay A$38M – $4.7M covered by insurance – to settle a class action brought in 2021.

02 Jul 2024 09:54 (AEST)

Mayne Pharma Group (ASX:MYX) announces on-market buyback program

Mayne Pharma (ASX:MYX) has announced an on-market share buyback program for up to 10 per cent of the company's issued capital.

10 May 2023 15:03 (AEST)

Mayne Pharma (ASX:MYX) completes sale of US retail generics business for US$90 million

Mayne Pharma (ASX:MYX) has completed the sale of its US retail generics portfolio for up to US$90 million (A$134 million).

11 Apr 2023 10:31 (AEST)



(20min delay)
Last
$4.60 		Change
-0.170(3.56%) 		Mkt cap ! $400.6M
Open High Low Value Volume
$4.71 $4.73 $4.57 $470.1K 101.1K

Buyers (Bids)

No. Vol. Price($)
4 719 $4.60
 

Sellers (Offers)

Price($) Vol. No.
$4.62 1055 6
View Market Depth
Last trade - 15.26pm 02/10/2024 (20 minute delay) ?
Last
$4.61 		  Change
-0.170 ( 3.12 %)
Open High Low Volume
$4.71 $4.75 $4.57 12709
Last updated 15.48pm 02/10/2024 ?
MYX (ASX) Chart

Top Stories

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one Cobalt Blue has released estimates for what it would take to get its proposed Kwinana refinery off the ground, seeing CapEx of $60M.
SPC to merge with Original Juice Co and Nature One Dairy The Original Juice Co Ltd has set up a transaction which will see it merge with Aussie icon SPC Global and Singapore-based Nature One Dairy
Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia Coda Minerals (ASX:COD) CEO, Chris Stevens, joins The Market Online to discuss the company's current rights issue, and how the capital from this raise will be used to further its copper exploration in South Australia. In addition, Chris talks through the journey the company has taken over the last few years since listing until now.
Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals Actinogen Medical is developing a promising oral treatment for Alzheimer's and depression and is accelerating clinical trials with new capital.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.